What really is blood compatibility?
The criteria for nonthrombogenicity are classically defined as long clotting times and minimal platelet deposition. The inability to point to unequivocal progress in the development of truly nonthrombogenic materials, highlights the inadequacy if not actually invalidity of these criteria. Our approach is to define nonthrombogenicity in terms of: (1) a thrombin production rate constant, kp < 10(-4) cm s(-1); (2) low platelet consumption and low degree of platelet activation (e.g., microparticle formation); (3) perhaps some platelet spreading; and (4) low complement and leukocyte activation. Only when the target becomes clear, will it be possible to identify clear strategies for producing the materials we need.
Department of Chemical Engineering and Applied Chemistry, Institute of Biomaterials and Biomedical Engineering, University of Toronto, Canada.
M V
MV
Sefton
C H
CH
Gemmell
M B
MB
Gorbet
D000818:Animals; D001672:Biocompatible Materials / Q000494:pharmacology / Q000592:standards*; D001769:Blood; D001798:Blood Proteins / Q000378:metabolism; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects; D013923:Thromboembolism / Q000139:chemically induced
D001672:Biocompatible Materials; D001798:Blood Proteins